The effect of clonidine as an adjunct to lidocaine on postoperative pain control following root canal treatment

Submission date	Recruitment status	Prospectively registered
10/12/2016	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
29/12/2016	Completed	[X] Results
Last Edited	Condition category	Individual participant data
19/01/2023	Oral Health	

Plain English summary of protocol

Background and study aims

Root canal treatment is a common dental procedure used to treat an infection at the centre of a tooth in an area called the root canal system. The infection can be extremely painful, and the only way of treating it is to remove the bacteria from the root canal system (root canal treatment) or to remove the tooth. Root canal treatment is generally considered to be an extremely painful procedure, and so modern research into root canal treatment generally focusses on decreasing the pain for patients who may already be nervous of the treatment. The aim of this study is to investigate the pain relieving qualities of a new combination of clonidine (an anti-anxiety medication used in general surgery) with 2% lidocaine (the typical numbing medication used in the dental office) compared to normal treatment.

Who can participate?

Adults who require root canal treatment.

What does the study involve?

Participants are randomly allocated to one of two groups who each receive a different numbing treatment before having their root canal surgery. Those in the first group receive an injection into the gum (inferior alveolar nerve block) to numb the mouth using lidocaine (a local anaesthetic used by dentists) with epinephrine (adrenaline), which is the usual solution used for this procedure. Those in the second group receive the injection with the new solution made up of clonidine (an anti-anxiety medication used in general surgeries) and lidocaine. In both groups, their level of pain is assessed using a scale before the injection and then 6, 12, 24, 36, 48, and 72 hours afterwards.

What are the possible benefits and risks of participating?

The benefits to the patient include receiving a root canal performed by a root canal specialist. The risks involved are minimal as the patient requires the root canal to remove the dental pain and infection, and the novel anesthetic (clonidine + 2% lidocaine) has been proven to be safe in other studies.

Where is the study run from?
Isfahan University of Medical Sciences (Iran)

When is the study starting and how long is it expected to run for? September 2014 to January 2016

Who is funding the study? Isfahan University of Medical Sciences (Iran)

Who is the main contact? Professor Elham Shadmehr elham.shadmehr@gmail.com

Contact information

Type(s)

Scientific

Contact name

Prof Elham Shadmehr

ORCID ID

https://orcid.org/0000-0003-3985-6570

Contact details

University of California 707 Parnassus ave, D3214 San Francisco United States of America 94143

elham.shadmehr@gmail.com

Additional identifiers

Protocol serial number

142287

Study information

Scientific Title

The effect of clonidine as an adjunct to lidocaine on postoperative pain control following root canal treatment: a prospective randomized double-blind study

Study objectives

Addition of clonidine to 2% lidocaine will reduce postoperative pain after root canal treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Isfahan University of Medical Sciences, 14/04/2014, ref: 142287

Study design

Randomized controlled double-blind clinical trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Postoperative pain after root canal treatment

Interventions

Patients are randomised to one of two groups.

Group 1: Patients receive 1.8 mL of 2% lidocaine with clonidine (15 μ g/mL) using a conventional inferior alveolar nerve block (IANB).

Group 2: Patients receive 1.8 mL of 2% lidocaine with epinephrine (1:80,000) using a conventional inferior alveolar nerve block (IANB).

All treatments are completed in a single-visit appointment. Pain scores are recorded preoperatively and at 6, 12, 24, 36, 48, and 72 hours after endodontic treatment using a Heft-Parker visual analog scale (VAS). Also, the total number of tablets of analgesics consumed by the patient are also recorded and analyzed by chi-squared, paired t-test and repeated measure of ANOVA (p<0.05).

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Clonidine, lidocaine

Primary outcome(s)

- 1. Pain scores, recorded using a Heft-Parker visual analog scale (VAS) preoperatively and at 6, 12, 24, 36, 48, and 72 hours after endodontic treatment
- 2. Number of pain medications consumed are recorded continuously for 72 hours postoperatively

Key secondary outcome(s))

Duration of postoperative pain is assessed using a visual analog scale (VAS) preoperatively and at 6, 12, 24, 36, 48, and 72 hours

Completion date

15/01/2016

Eligibility

Key inclusion criteria

- 1. Adult patients (18 years of age or older)
- 2. In good medical condition (American Society of Anesthesiologists classification 1)
- 3. Diagnosed with symptomatic irreversible pulpitis and normal/symptomatic apical periodontitis at the mandibular first or second molars

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

100

Key exclusion criteria

- 1. Patients with active signs of oral infections or inflammation
- 2. History of addiction or use of ß blockers
- 3. Patients taking any medications that could affect anesthetic assessment (analgesics or opioids at least one week before treatments)
- 4. Patients with allergies or contraindications to the use of clonidine, epinephrine or ibuprofen
- 5. Female patients who were pregnant or breastfeeding
- 6. Patients with no response to cold testing
- 7. Perirapical pathosis (other than a widened periodontal ligament)
- 8. No vital coronal pulp tissue upon access cavity preparation (partial necrosis)

Date of first enrolment

15/11/2014

Date of final enrolment

15/01/2016

Locations

Countries of recruitment

Iran

Study participating centre Isfahan University of Medical Sciences

Hezar Jarib Street Isfahan Iran 8168913673

Sponsor information

Organisation

Isfahan University of Medical Sciences

ROR

https://ror.org/04waqzz56

Funder(s)

Funder type

University/education

Funder Name

Isfahan University of Medical Sciences

Alternative Name(s)

, IUMS

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

Iran

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Elham Shadmehr (Eshadmehr@buffalo.edu)

IPD sharing plan summary

Available on request

Study outputs

Output typeDetailsDate createdDate addedPeer reviewed?Patient-facing?Results article05/07/202119/01/2023YesNoParticipant information sheet11/11/202511/11/2025NoYes